← All trials
NCT05559450
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Jan 1, 2024
- Completion date
- Jan 31, 2026
- First posted
- Sep 29, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Soochow UniversityLead sponsor
- Nanjing UniversityCollaborator
- The First People's Hospital of ChangzhouCollaborator
- Fujian Medical UniversityCollaborator
- Soochow UniversityOverall official - principal investigator
- Soochow UniversityReponsible party - principal investigator
- Southeast UniversityCollaborator
- Wannan Medical CollegeCollaborator
- Wuxi People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.